摘要
目的 研究 β 七叶皂苷对大鼠脑缺血再灌注损伤的保护作用是否与其抑制炎症反应有关。方法 大鼠缺血前分别给予 β 七叶皂苷 15 ,30 ,6 0mg·kg- 1,ig ,7d ,末次给药 1h后线栓法制备大脑中动脉阻断短暂局灶性脑缺血模型 ,缺血 2h ,再灌注 2 2h ,评价神经功能状态和脑梗死范围 ;用伊文思兰法测定脑缺血 2h再灌 3h后对血脑屏障的损伤程度。用放射免疫、酶联免疫分析及免疫印迹的方法测定大脑缺血区白介素 8(IL 8) ,肿瘤坏死因子 α(TNF α)及核因子 κB(NF κB)的表达。结果 β 七叶皂苷能显著降低脑缺血再灌注后脑梗死体积 ,改善神经功能症状 ,其脑内IL 8,TNF α的活性显著降低 ,NF κB的表达显著减少 ,与模型组相比具有统计学显著意义。结论 β 七叶皂苷通过抑制炎性物质的表达和释放对大鼠脑缺血再灌注损伤具有明显保护作用。
AIM To investigate if the beneficial effects of β-aescin on i schemia/reperfusion (I/R) induced cerebral injury are related to the inhibition of expressions of pro-inflammatory cytokines. METHODS Rats were pr etreated ig with β-aescin for 7 d and then subjected to cerebral I/R injury in duced by a middle cerebral artery occlusion. The infarct volume and the neurolog ical deficit were determined by the method of TTC staining and the Longa′s scor e. The permeability of the blood-brain barrier was evaluated by measurement of the Evans blue (EB) content in the brain with spectrophotometer. The serum conte nts of interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) protein we re determined by radioimmunoassay and ELISA assay. The expression of nuclear fac tor-κB (NF-κB) was evaluated with Western blot. RESULTS β-Aes cin significantly reduced infarct volume (P<0.05 or P<0. 01), ameliorated the ne urological deficit and reduced the permeability of blood-brain barrier (P < 0.05). Pretreated with β-aescin 30 and 60 mg·kg -1, the serum con tent of IL-8 and the expressions of TNF-α and NF-κB protein in brain tissue were significantly decreased (P<0.05). CONCLUSION β- Aescin has protective effects on cerebral injury through inhibiting the expressi on and release of the inflammatory mediators after I/R injury.
出处
《中国药理学与毒理学杂志》
CAS
CSCD
北大核心
2005年第1期1-6,共6页
Chinese Journal of Pharmacology and Toxicology
关键词
Β-七叶皂苷
白介素-8
肿瘤坏死因子
核
因子-ΚB
脑缺血
aescin
interleukin-8
tumor necrosis factor
nu clear factor-κB
brain ischemiaInhibitory effect of β-aescin on inflammatory process followin gfocal cerebral ischemia-reperfusion in rats$$$$ HU Xia-Min, ZENG Fan-Dian*(Institute of Clinica
